162 related articles for article (PubMed ID: 29665645)
1. MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer.
Ma X; Zou L; Li X; Chen Z; Lin Q; Wu X
Biomed Pharmacother; 2018 Mar; 99():445-450. PubMed ID: 29665645
[TBL] [Abstract][Full Text] [Related]
2. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
3. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73.
Gao Q; Zheng J
Biomed Pharmacother; 2018 Jan; 97():528-534. PubMed ID: 29091904
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer.
Feng Q; He P; Wang Y
Gene; 2018 Jun; 658():152-158. PubMed ID: 29518547
[TBL] [Abstract][Full Text] [Related]
5. Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells.
Qiu X; Wang W; Li B; Cheng B; Lin K; Bai J; Li H; Yang G
BMC Cancer; 2019 Jan; 19(1):27. PubMed ID: 30621625
[TBL] [Abstract][Full Text] [Related]
6. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.
Zhong B; Sallman DA; Gilvary DL; Pernazza D; Sahakian E; Fritz D; Cheng JQ; Trougakos I; Wei S; Djeu JY
Mol Cancer Ther; 2010 Jun; 9(6):1831-41. PubMed ID: 20501799
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
[TBL] [Abstract][Full Text] [Related]
8. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.
Patterson SG; Wei S; Chen X; Sallman DA; Gilvary DL; Zhong B; Pow-Sang J; Yeatman T; Djeu JY
Oncogene; 2006 Oct; 25(45):6113-22. PubMed ID: 16652143
[TBL] [Abstract][Full Text] [Related]
9. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
10. Clusterin mediates TRAIL resistance in prostate tumor cells.
Sallman DA; Chen X; Zhong B; Gilvary DL; Zhou J; Wei S; Djeu JY
Mol Cancer Ther; 2007 Nov; 6(11):2938-47. PubMed ID: 18025278
[TBL] [Abstract][Full Text] [Related]
11. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
Corcoran C; Rani S; O'Driscoll L
Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
[TBL] [Abstract][Full Text] [Related]
12. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1.
Zhang G; Tian X; Li Y; Wang Z; Li X; Zhu C
Biomed Pharmacother; 2018 Jan; 97():736-744. PubMed ID: 29102917
[TBL] [Abstract][Full Text] [Related]
13. Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.
Gu X; Xue JQ; Han SJ; Qian SY; Zhang WH
Cancer Biomark; 2016; 16(3):395-403. PubMed ID: 27062696
[TBL] [Abstract][Full Text] [Related]
14. Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.
Yang Z; Chen JS; Wen JK; Gao HT; Zheng B; Qu CB; Liu KL; Zhang ML; Gu JF; Li JD; Zhang YP; Li W; Wang XL; Zhang Y
J Exp Clin Cancer Res; 2017 Dec; 36(1):178. PubMed ID: 29216925
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.
Puhr M; Hoefer J; Schäfer G; Erb HH; Oh SJ; Klocker H; Heidegger I; Neuwirt H; Culig Z
Am J Pathol; 2012 Dec; 181(6):2188-201. PubMed ID: 23041061
[TBL] [Abstract][Full Text] [Related]
16. The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells.
Wang X; Yang B; Ma B
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1025-1031. PubMed ID: 27686228
[TBL] [Abstract][Full Text] [Related]
17. Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis.
Li B; Jin X; Meng H; Hu B; Zhang T; Yu J; Chen S; Guo X; Wang W; Jiang W; Wang J
Oncotarget; 2017 Jul; 8(29):47849-47860. PubMed ID: 28599307
[TBL] [Abstract][Full Text] [Related]
18. Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells.
Shi GH; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Xiao WJ; Ma CG
Acta Pharmacol Sin; 2010 Jul; 31(7):867-73. PubMed ID: 20581857
[TBL] [Abstract][Full Text] [Related]
19. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer.
Shiota M; Zoubeidi A; Kumano M; Beraldi E; Naito S; Nelson CC; Sorensen PH; Gleave ME
Mol Cancer Res; 2011 Dec; 9(12):1755-66. PubMed ID: 21987172
[TBL] [Abstract][Full Text] [Related]
20. Glyceryl trinitrate‑induced cytotoxicity of docetaxel‑resistant prostatic cancer cells is associated with differential regulation of clusterin.
Bouaouiche S; Magadoux L; Dondaine L; Reveneau S; Isambert N; Bettaieb A; Jeannin JF; Laurens V; Plenchette S
Int J Oncol; 2019 Apr; 54(4):1446-1456. PubMed ID: 30720069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]